Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment

UROonco25

19 - 21 Jun 2025

Published: 19 Jun 2025

Views: 66

Rating:

Save

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Interactive industry seminar from UROonco25 in Sevilla, featuring:

Welcome and introductions - Prof Bernardo Herrera Imbroda
HR-NMIBC after BCG treatment: insights from a patient case - Prof Bernardo Herrera Imbroda
At the crossroads: BCG rechallenge vs chemotherapy in BCG-unresponsive patients - Prof Bernardo Herrera Imbroda and Dr Géraldine Pignot
Beyond the horizon: current and future treatment landscape after BCG - Dr Géraldine Pignot
Q&A and closing - Dr Géraldine Pignot

Click here for the EAU and IBCG guidelines overview: Classification and management of patients with NMIBC

This industry symposium is funded and organised by Johnson & Johnson in EMEA and is intended for healthcare professionals only.

This video is not available for HCPs based in Spain.

Related Videos

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

Challenges of managing patients with NMIBC: from risk stratification to...

Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat

Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC

Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC ( Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

More from ecancer